Catalogue

Background
Ibuprofen is an anti-inflammatory drug used for pain relief, fever reduction and against swelling. It is one of the most sold over-the-counter drugs. It is found in the environment, especially in the water environment in the neighbourhood of large cities and hospitals.

Source
Rabbit immune serum

Immunogen: BSA-Ibuprofen derivative conjugate

Product
Each vial contains 0.1 ml 10mg/ml serum containing 0.02% sodium azide

Specificity
Target: Ibuprofen, CAS no.: 15687-27-1, Solubility: Organic solvents, PEGs.

Species Reactivity: Compound tested % Cross- reactivity Bezafibrate 0.4% Gemfibrozil 0.2% Bisphenol A 0.6% Ibuprofen 100% Carazolol <0.1% Metoprolol 0.1% Chlorpyrifos 0.3% Naproxen 2.2% Clofibrinic acid 0.3% Nonylphenol 1.3% Diclofenac <0.1% Octylphenol 0.6% Erythromycine 0.1% Propanolol 0.1% Fenitrothion 0.5% Vinclozolin <0.1% Fenofibrate 0.5% Zearalenon 0.2%

Applications
Dilution of 1/7,000 from the delivered immune serum. (The titer is defined as the dilution that gives 50 % of the absorbance from the maximum absorbance when tested with ELISA). Suggested concentration to use in ELISA : 1/5,000 from the delivered solution. Plates are coated with 400 ng/ml OVA- derivative. HRP-conjugated anti-rabbit IgG as a tracer 1/8,000

Storage
Store at 4 °C or aliquot and store at -20 °C for longer periods. Precautions should be taken upon storage for longer periods. Problems of long term stability may occur with highly diluted solutions. For long storage purposes in solution the addition of sodium azide at 0.02 % is advised with the appropriate precautions of use.

Shipping Conditions: Ship at ambient temperature.

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Nordic-MUbio​ accepts no liability for any inaccuracies or omissions in this information.

References
1. J.G.M. Derksen, G.M. van Eijnatten, J Lahr, P. van der Linde and A.G.M. Kroon - Enviromental Effects of Human Pharmaceuticals, p 225, RIWA Report 2000.051, Leleystad, The Netherlands 2. Eline P. Meulenberg, Gijsbert O.H. Peelen, Eddie Lukkien and Kees Koopal – Immunochemical detection methods for bioactive pollutants – Intern. J. Environ. Anal. Chem. Vol. 85, 2005, 861-870